Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

7792 ARTÍCULOS , VIENDO DEL 6526 AL 6540

Basal ganglia contributions to social cognition: evidence from movement disorders

Eddy CM.

Cogn Neuropsychiatry. 2025 Jan;30(1):1-14. doi: 10.1080/13546805.2025.2490054. Epub 2025 Apr 11.

Peroxisome proliferator-activated receptors (PPARs) agonists as promising neurotherapeutics

Ghannam IAY, Hassan RM, Abdel-Maksoud MS.

Bioorg Chem. 2025 Mar;156:108226. doi: 10.1016/j.bioorg.2025.108226. Epub 2025 Jan 30.

Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease

Frank S, Testa CM, Goldstein J, Kayson E, Leavitt BR, Oakes D, O'Neill C, Whaley J, Gross N, Chaijale N, Barash S, Gordon MF; Huntington Study Group/ARC-HD Investigators and Coordinators.

CNS Drugs. 2025 Feb;39(2):185-195. doi: 10.1007/s40263-024-01139-3. Epub 2025 Jan 18.

Efficacy and safety of vesicular monoamine transporter 2 inhibitors for Huntington's disease chorea based on network meta-analysis

Huang J, Chen FF, Wen SY, Tao P, Meng C, Chen W, Zhou CQ.

Front Pharmacol. 2025 Sep 24;16:1637577. doi: 10.3389/fphar.2025.1637577. eCollection 2025.

Advances in Neurodegenerative Disease Therapy: Stem Cell Clinical Trials and Promise of Engineered Exosomes

Isik S, Osman S, Yeman-Kiyak B, Shamshir SRM, Sanchez NME.

CNS Neurosci Ther. 2025 Sep;31(9):e70577. doi: 10.1111/cns.70577.

Exploring Novel Therapeutic Avenues: Drug Repurposing for Neurodegenerative Movement Disorders

Bassi P, Rana S, Sapra V, Raina A, Kumar P, Devi S.

Curr Drug Res Rev. 2025;17(3):375-393. doi: 10.2174/0125899775327220240822111611.

Short-chain fatty acids in Huntington's disease: Mechanisms of action and their therapeutic implications

Saadh MJ, Ahmed HH, Kareem RA, Sanghvi G, Ganesan S, Agarwal M, Kaur P, Taher WM, Alwan M, Jawad MJ, Hamad AK.

Pharmacol Biochem Behav. 2025 Apr;249:173972. doi: 10.1016/j.pbb.2025.173972. Epub 2025 Feb 19.

The Hsp40 co-chaperone DNAJC7 modifies polyglutamine but not polyglycine aggregation

Ramani B, Ehsani K, Kampmann M.

bioRxiv [Preprint]. 2025 Aug 12:2025.08.10.669490. doi: 10.1101/2025.08.10.669490.

Neurodegenerative diseases: Epigenetic regulatory mechanisms and therapeutic potential

Men J, Wang X, Zhou Y, Huang Y, Zheng Y, Wang Y, Yang S, Chen N, Yan N, Duan X.

Cell Signal. 2025 Jul;131:111715. doi: 10.1016/j.cellsig.2025.111715. Epub 2025 Mar 13.

Multitarget Compounds Designed for Alzheimer, Parkinson, and Huntington Neurodegeneration Diseases

Katsoulaki EE, Dimopoulos D, Hadjipavlou-Litina D.

Pharmaceuticals (Basel). 2025 Jun 1;18(6):831. doi: 10.3390/ph18060831.

Mitochondrial Aging in the CNS: Unravelling Implications for Neurological Health and Disease

Steffan D, Pezzini C, Esposito M, Franco-Romero A.

Biomolecules. 2025 Aug 29;15(9):1252. doi: 10.3390/biom15091252.

Huntington's Disease and Dentistry: A Review of Its Etiology, Clinical Presentation, Symptomatic Pharmacotherapy, and Dental Management

Duble H, Ouanounou A.

Spec Care Dentist. 2025 Mar-Apr;45(2):e70024. doi: 10.1111/scd.70024.

Lipidomics of Huntington's Disease: A Comprehensive Review of Current Status and Future Directions

Yilmaz A, Akyol S, Ashrafi N, Saiyed N, Turkoglu O, Graham SF.

Metabolites. 2025 Jan 2;15(1):10. doi: 10.3390/metabo15010010.

The Role of MicroRNAs in Neurodegeneration: Insights from Huntington's Disease

Mansour RM, Shaker AAS, Abulsoud AI, Mageed SSA, Ashraf A, Elsakka EGE, Dahab MI, Sadek MM, Awad FA, Lutfy RH, Elimam H, Faraag AHI, Nassar YA, Ali MA, Mohammed OA, Abdel-Reheim MA, Doghish AS.

Mol Neurobiol. 2025 Jul;62(7):8502-8517. doi: 10.1007/s12035-025-04750-7. Epub 2025 Feb 26.

Abnormal neurodevelopment predisposes to cortical hyperexcitability in Huntington's disease

Cepeda C, Barry J, Holley SM.

J Huntingtons Dis. 2025 Aug 19:18796397251366891. doi: 10.1177/18796397251366891. Online ahead of print.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias